Mitchell Horwitz, MD, on Cost-Effectiveness of Omidubicel for Allo-HCT
The professor of medicine at Duke Cancer Institute discussed uptake and research with the cord blood therapy since its approval.
Mitchell Horwitz, MD, on Omidubicel’s Value for Racially Diverse Patients Receiving AlloHCT
The professor of medicine at Duke Cancer Institute discussed findings from an early access program of the therapy, recently approved as Omisirge.